Suppr超能文献

抗肿瘤药物引起的超敏反应的预防与管理。

Prevention and management of antineoplastic-induced hypersensitivity reactions.

作者信息

Zanotti K M, Markman M

机构信息

Department of Obstetrics and Gynecology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.

出版信息

Drug Saf. 2001;24(10):767-79. doi: 10.2165/00002018-200124100-00005.

Abstract

Acute hypersensitivity reactions (HSRs) are an unpredictable and potentially catastrophic complication of treatment with chemotherapeutic agents. Reactions may affect any organ system in the body and range widely in severity from mild pruritus to systemic anaphylaxis. Certain classes of chemotherapeutic agents, such as the taxanes, platinum compounds, asparaginases, and epipodophyllotoxins are commonly associated with HSRs. The clinical characteristics of these high risk agents with respect to HSRs are discussed in this review. Protocols to prevent or reduce the severity of these reactions have been developed, but despite these attempts, HSRs will still happen. Should a reaction occur, it is imperative that it be recognised quickly in order to minimise exposure to the inciting agent and implement appropriate therapeutic and supportive measures. When a patient becomes sensitised to a chemotherapeutic agent, avoidance of re-exposure is the mainstay of future prevention. For sensitised patients who have derived clinically meaningful benefit from a particular agent, however, continuation of treatment with the agent is desirable. Options may include attempting a trial of desensitisation or treatment with a related compound. Virtually all patients demonstrating HSRs to paclitaxel and docetaxel are able to successfully tolerate re-treatment following discontinuation and administration of diphenhydramine and hydrocortisone. Re-treatment has generally been less successful with platinum compounds. with recurrent HSRs occurring in up to 50% of patients following desensitisation protocols. Patients sensitised to asparaginase are often able to tolerate the alternative preparations, Erwinia carotovora asparaginase or polyethylene glycol-modified Escherichia coli asparaginase. There is very little experience with re-treatment following sensitisation to the epipodophyllotoxins. As re-treatment may have serious consequences, careful consideration of the risks and benefits of these strategies is imperative when deciding among these options.

摘要

急性超敏反应(HSRs)是化疗药物治疗中一种不可预测且可能具有灾难性的并发症。反应可能影响身体的任何器官系统,严重程度范围广泛,从轻度瘙痒到全身性过敏反应。某些化疗药物类别,如紫杉烷类、铂类化合物、天冬酰胺酶和鬼臼毒素类,通常与HSRs相关。本综述讨论了这些高风险药物在HSRs方面的临床特征。已经制定了预防或降低这些反应严重程度的方案,但尽管有这些努力,HSRs仍会发生。一旦发生反应,必须迅速识别,以尽量减少对诱发剂的接触,并实施适当的治疗和支持措施。当患者对化疗药物致敏时,避免再次接触是未来预防的主要方法。然而,对于从特定药物中获得临床显著益处的致敏患者,继续使用该药物治疗是可取的。选择可能包括尝试脱敏试验或用相关化合物治疗。几乎所有对紫杉醇和多西他赛表现出HSRs的患者在停药并给予苯海拉明和氢化可的松后都能够成功耐受再次治疗。铂类化合物的再次治疗通常不太成功,脱敏方案后高达50%的患者会出现复发性HSRs。对天冬酰胺酶致敏的患者通常能够耐受替代制剂,即胡萝卜软腐欧文氏菌天冬酰胺酶或聚乙二醇修饰的大肠杆菌天冬酰胺酶。对鬼臼毒素类致敏后的再次治疗经验非常少。由于再次治疗可能会产生严重后果,在决定这些选择时,必须仔细考虑这些策略的风险和益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验